Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Q2 2026 Earnings Presentation
18 slides from Quidelortho's earnings presentation, Aug 6, 2026
Slide 1: Second Quarter 2026 Financial Results
August 6, 2026 QuidelOrtho Second Quarter 2026 Financial Results © 2026 QuidelOrtho Corporation. All rights reserved. | 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are
Slide 3: Basis of Presentation
Basis of Presentation • 2026 financials are as of the three and six months ended June 28, 2026 and 2025 financials are as of the three and six months ended June 29, 2025. • Revenue growth rates are shown on a constant currency basis unless otherwise noted. The term "constant currency" means we have
Slide 4: Q2 2026 Revenue Highlights
Q2 2026 Revenue Highlights Across Highly Across Key Healthcare Recurring Regions Settings Revenue $631M $631M $631M 2% y/y 2% y/y 2% y/y Constant Currency Constant Currency Constant Currency Q2 2026 Financial Results Presentation | August 6, See Non-GAAP Financial Measures on slide 2, Basis of Prese
Slide 5: YTD 2026 Revenue Highlights
YTD 2026 Revenue Highlights Across Highly Across Key Healthcare Recurring Regions Settings Revenue $1.25B $1.25B $1.25B (6)% y/y (6)% y/y (6)% y/y Constant Currency Constant Currency Constant Currency Q2 2026 Financial Results Presentation | August 6, See Non-GAAP Financial Measures on slide 2, Basi
Slide 6: Q2 2026 Financial Results
Q2 2026 Financial Results Adj Operating Expenses Adj EBITDA Adj Diluted EPS Cash $219M $129M $0.13 $123M Adj. EBITDA Margin Free Cash Flow 2% y/y 20.5% 8% y/y $(136)M Total Net Debt SM&A Adj Gross Profit Margin Adj Tax Rate $2.8B $174M | 2% y/y 44.4% | (130) bps y/y 24.9% Net Debt to Adj EBITDA 4.9x
Slide 7: YTD 2026 Financial Results
YTD 2026 Financial Results Adj Operating Expenses Adj EBITDA Adj Diluted EPS Free Cash Flow $446M $238M $0.10 $(203)M Adj. EBITDA Margin —% y/y 19.0% (88)% y/y (197)% y/y SM&A Adj Gross Profit Margin Adj Tax Rate Operating Cash Flow $359M | 2% y/y 44.1% | (390) bps y/y 24.8% $(144)M R&D Depreciation
Slide 8: FY 2026 Financial Guidance
FY 2026 Financial Guidance As of 8/6/2026 Financial Guidance FY 2026 Total Revenues (Reported) $2.52 - $2.60B Adjusted EBITDA $540 - $560M Adjusted EBITDA Margin 21% - 22% Adjusted Diluted EPS $0.65 - $0.90 Free Cash Flow Withdrawn Q2 2026 Financial Results Presentation | August 6, See Forward-Looki
Slide 9: Appendix
Appendix © 2026 QuidelOrtho Corporation. All rights reserved. | 9
Slide 10: Non-GAAP Adjustments
Non-GAAP Adjustments Fiscal Quarter Year to Date In millions Q2 2026 Q2 2025 Q2 2026 Q2 2025 Employee compensation charges $ 2.1 $ — $ 4.4 $ — Accelerated depreciation 2.1 1.0 4.1 1.0 Incremental depreciation on PP&E fair value adjustment 1.7 3.3 3.5 6.6 Amortization of deferred cloud computing impl
Slide 11: Q2 2026 Non-GAAP Reconciliation
Q2 2026 Non-GAAP Reconciliation Fiscal Quarter Q2 2026 Fiscal Quarter Q2 2025 In millions GAAP Adjustments (1) Non-GAAP GAAP Adjustments (1) Non-GAAP Gross profit $ 272.9 $ 7.0 $ 279.9 $ 274.9 $ 5.6 $ 280.5 Selling, marketing and administrative 189.7 (15.8) 173.9 178.0 (8.0) 170.0 Research and devel
Slide 12: Q2 2026 YTD Non-GAAP Reconciliation
Q2 2026 YTD Non-GAAP Reconciliation Year to Date Q2 2026 Year to Date Q2 2025 In millions GAAP Adjustments (1) Non-GAAP GAAP Adjustments (1) Non-GAAP Gross profit $ 536.7 $ 14.4 $ 551.1 $ 618.2 $ 9.2 $ 627.4 Selling, marketing and administrative 389.0 (30.3) 358.7 365.0 (14.8) 350.2 Research and dev
Slide 13: Revenue by Geography
Revenue by Geography Three Months Ended In millions 2025 2026 Second Quarter Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant Change Impact Currency (1) North America $406.7 $310.7 $381.4 $390.1 $328.9 $327.4 5.4% (0.4)% 5.8% EMEA 88.9 87.3 91.8 92.7 92.5 91.2 4.5% 3.0% 1.5% China 75.0 83.4 84.6 91.7 63.
Slide 14: Revenue by Business Unit
Revenue by Business Unit Three Months Ended In millions 2025 2026 Second Quarter Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant Change Impact Currency (1) Labs $373.0 $369.7 $373.8 $389.2 $353.1 $382.9 3.6% 1.2% 2.4% Immunohematology 128.5 132.3 142.0 141.0 138.3 134.2 1.4% 0.7% 0.7% Donor Screening 12
Slide 15: Revenue by Respiratory and Non-Respiratory
Revenue by Respiratory and Non-Respiratory Three Months Ended In millions 2025 2026 Second Quarter Q1 Q2 Q3 Q4 Q1 Q2 Percent Currency Constant Change Impact Currency (1) Respiratory Revenue $119.8 $46.7 $112.3 $123.3 $67.9 $47.9 2.6% 0.1% 2.5% Non-Respiratory Revenue 573.0 567.2 587.6 600.3 551.9 58
Slide 16: Non-GAAP Reconciliations
Non-GAAP Reconciliations Three Months Ended In millions June 28, 2026 June 29, 2025 Percent Change Currency Impact Constant Currency (1) Total revenues $630.9 $613.9 2.8% 0.9% 1.9% In millions China revenue 67.8 83.4 (18.7)% 4.6% (23.3)% Total revenues excluding China $563.1 $530.5 6.1% 0.2% 5.9% Th
Slide 17: Non-GAAP Reconciliations – Adjusted EBITDA
Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Quarter Year to Date In millions Q2 2026 Q2 2025 Q2 2026 Q2 2025 Net loss $ (92.9) $ (255.4) $ (184.7) $ (268.1) Depreciation and amortization 116.7 110.3 229.6 217.4 Interest expense, net 54.7 40.5 105.8 80.5 Provision for income taxes 11.7 25.8 24.
Slide 18: quidelortho.com
Ly SIMIC ENO Tgy quidelortho.co